Regulatory label· 2025

EGRIFTA WR (tesamorelin) prescribing information

U.S. Food and Drug Administration

FDA Prescribing Information

Evidence level: regulatory
Verification: verified

Summary

Official United States prescribing information for tesamorelin.

Limitations

Applies to the approved formulation and licensed indication rather than general weight loss or performance use.

Linked peptides

Tesamorelin

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.